EGF and neoplasm: The EGF DCX/RSV LPHNPs also showed a better antitumor activity compared to free drugs and DCX/RSV LPHNPs using a lung cancer-bearing mice model, as indicated by the lower tumor volume, higher tumor growth inhibition ratios and absence of weight loss in mice.